Table 1.
Demographic characteristics of the participants.
| Day-7 | Day-28 | Day-60 | Day-90 | Day-150 | |
|---|---|---|---|---|---|
| (1 week post 1st dose) | (1 week post 2nd dose) | ||||
| Participants (all)* | 225 | 220 | 211 | 210 | 208 |
| Age | |||||
| 20–39 y.o. | 97 (43.1%) | 92 | 84 | 84 | 82 |
| 40–59 y.o. | 110 (48.9%) | 110 | 109 | 108 | 109 |
| 60–y.o. | 18 (8.0%) | 18 | 18 | 18 | 17 |
| Gender | |||||
| Men | 68 (30.2%) | 68 | 63 | 61 | 62 |
| Women | 157 (69.8%) | 152 | 148 | 149 | 146 |
| Job | |||||
| Physicians | 36 (16.0%) | ||||
| Nurses | 125 (55.6%) | ||||
| Others | 64 (28.4%) | ||||
*None of the participants were in immunodeficient states or were receiving immunosuppressants or steroids. Two participants had previously experienced SARS-CoV-2 infection and were excluded from the present study since day-28. None of other participants experienced COVID-19-related symptoms and proved to be negative for antibodies against serum SARS-CoV-2 nucleocapsid throughout the study period.